The analysis of titration studies in phase III clinical trials
- 1 May 1989
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 8 (5) , 583-591
- https://doi.org/10.1002/sim.4780080507
Abstract
Clinical trials commonly employ the titration design for certain drugs such as antihypertensives. In a Phase III trial the design has purposes distinct from those of a Phase I or II trial, as well as from those of a trial with a parallel design. In this paper we compare the titration design with the usual parallel design in their respective purposes for Phase III trials, explore the relevant questions addressed, and examine typical data from such trials. We also discuss work which focuses primarily on the Phase I or II titration trials. We formulate the problem in the framework of a one‐way contingency table augmented with incomplete data and obtain the maximum likelihood estimates of the parameters and their estimated variances/covariances via the EM algorithm. An example of a Phase III study of an antihypertensive agent illustrates the proposed procedure.Keywords
This publication has 8 references indexed in Scilit:
- Two approaches for the analysis of a titration study with a placebo controlCommunications in Statistics - Theory and Methods, 1988
- The analysis of a titration studyStatistics in Medicine, 1987
- The determination of practically useful doses of new drugs: Some methodological considerationsStatistics in Medicine, 1986
- On the Convergence Properties of the EM AlgorithmThe Annals of Statistics, 1983
- Finding the Observed Information Matrix When Using the EM AlgorithmJournal of the Royal Statistical Society Series B: Statistical Methodology, 1982
- The conduct and principles of randomized clinical trialsControlled Clinical Trials, 1981
- Maximum Likelihood from Incomplete Data Via the EM AlgorithmJournal of the Royal Statistical Society Series B: Statistical Methodology, 1977
- Inference and missing dataBiometrika, 1976